Vol 52, No 6 (2021)
Short communication
Published online: 2021-11-17

open access

Page views 5981
Article views/downloads 308
Get Citation

Connect on Social Media

Connect on Social Media

Long-term follow-up of pediatric patients with EBV-related post-transplant lymphoproliferative disorder

Przemysław Gałązka1, Małgorzata Szafrańska2, Kamila Jaremek1, Dorota Rutkowska3, Krzysztof Czyżewski1, Robert Dębski1, Monika Richert-Przygońska1, Tomasz Grzybowski4, Joanna Konieczek1, Jan Styczynski1
Acta Haematol Pol 2021;52(6):597-600.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999; 94(7): 2208–2216.
  2. Styczyński J. Infectious complications in children and adults with hematological malignancies. Acta Haematol Pol. 2019; 50(3): 167–173.
  3. Styczyński J. ABC of viral infections in hematology: focus on herpesviruses. Acta Haematol Pol. 2019; 50(3): 159–166.
  4. Styczyński J. Limfadenopatia u dzieci i dorosłych: zasady postępowania diagnostycznego. Acta Haematol Pol. 2019; 50(3): 98–102.
  5. Styczynski J, Reusser P, Einsele H, et al. Second European Conference on Infections in Leukemia. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant. 2009; 43(10): 757–770.
  6. Styczynski J, van der Velden W, Fox CP, et al. Sixth European Conference on Infections in Leukemia, a joint venture of the Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation (EBMT-IDWP), the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (EORTC-IDG), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016; 101(7): 803–811.
  7. Styczynski J, Gil L, Tridello G, et al. Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Response to rituximab-based therapy and risk factor analysis in Epstein Barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2013; 57(6): 794–802.
  8. Styczyński J, Kałwak K, Czyżewski K, et al. Results of therapy with anti-CD20 antibodies in EBV-related post-transplant lymphoproliferative disorder. Post Nauk Med. 2014; 27(4): 261–264.
  9. Cheson BD, Pfistner B, Juweid ME, et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5): 579–586.
  10. Kinch A, Hallböök H, Arvidson J, et al. Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT. Leuk Lymphoma. 2018; 59(5): 1172–1179.
  11. Salooja N, Shoham Z, Dalle JH. Endocrine disorders, fertility and sexual health. In: Carreras E, Dufour C, Mohty M, Kroger N. ed. The EBMT Handbook: hematopoietic stem cell transplantation and cellular therapies. Springer, Cham 2019: 421–427.
  12. Styczynski J, Tridello G, Gil L, et al. Prognostic impact of Epstein-Barr virus serostatus in patients with nonmalignant hematological disorders undergoing allogeneic hematopoietic cell transplantation: the study of Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation. Acta Haematol Pol. 2020; 51(2): 73–80.